Savara and the PAP Foundation Form Global Partnership Which Will Support and Unite the Community of Individuals Afflicted with Pulmonary Alveolar Proteinosis (PAP) AUSTIN, Texas and LOS ANGELES, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, is pleased to announce a global partnership with the PAP Foundation, Inc., a non-profit patient advocacy organization dedicated to improving the lives of those affected by PAP, where Savara will serve as the inaugural sponsor of the foundation. In this capacity, Savara will be supporting the PAP Foundation’s efforts to unite, educate, organize and build the global PAP patient and physician community, including helping to further expand the PAP patient registry, as well as offering grant assistance to support educational awareness efforts, which include the 1st Annual National PAP Education Day, to be held concurrently with the 2018 Rare Lung Diseases Conference on Saturday, September 8th, 2018. “The PAP Foundation is grateful for Savara’s generous support and commitment, not only in helping our foundation provide education and awareness of PAP to the global patient and physician communities, but also as the only biotech company aggressively seeking effective FDA approved therapies for those afflicted by PAP,” said Christopher Hameetman, President of the PAP Foundation. “The PAP-patient community is further grateful to Savara for expediting its U.S. development strategy for Molgradex (inhaled GM-CSF), which we believe could be an effective treatment for autoimmune-PAP patients.” “We at Savara are proud to be a part of the Rare Disease community and are delighted to be joining the PAP Foundation on this collaborative, educational effort and the opportunity to positively impact the global PAP community,” said Rob Neville, CEO of Savara. “We believe there is a tremendous opportunity for meaningful impact and this partnership is a continuation of our proud commitment to support the patient communities we aim to serve and the organizations that provide patients, families and caregivers the critical support they need.” The Savara / PAP Foundation 1st Annual National PAP Education Day will be held concurrently with the 2018 Rare Lung Diseases Conference (RLDC) at the Cincinnati Marriott at Rivercenter located at 10 W Rivercenter Blvd., Covington, KY 41011 on Saturday, September 8, 2018 from 1:00 PM – 9:00 PM. Everyone in the PAP community is welcome and attendance is complimentary to any pulmonary clinicians and registered PAP patients, and their relatives and support persons (RLDC Tickets / Credentials are not required for this special event). For more details, or to register to attend the 1st Annual National PAP Education Day, please contact Brenna Carey, MS, PhD, PAP, Foundation Coordinator, either by phone: 513.636.8916, or via email: brennac@papfoundation.org. About the PAP FoundationThe PAP Foundation is a non-profit patient advocacy organization dedicated to research and education on effective therapies for Pulmonary Alveolar Proteinosis (PAP), and to improving the lives of those affected by PAP. PAP is a life-threatening lung disorder that affects men, women, and children. Through advocacy and collaboration with a focus on uniting the PAP patient community, the PAP Foundation promotes research and provides information and support for PAP patients, healthcare professionals, and the public. More information can be found on our website at www.papfoundation.org, and also on social media including Facebook and Twitter. About Savara Savara is an orphan lung disease company. Savara's pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara's management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma) Forward-Looking Statements Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding Savara’s support of the PAP Foundation’s efforts to unite, educate, organize and build the global PAP patient and physician community, including helping to further expand the PAP patient registry, Savara’s offering of grant assistance to support educational awareness efforts, including its 1st Annual National PAP Education Day, Savara being the only biotech company aggressively seeking effective FDA approved therapies for those afflicted by PAP, Savara expediting its U.S. development strategy for Molgradex, the belief that Molgradex could be an effective treatment for autoimmune-PAP patients, the belief that there is a tremendous opportunity for meaningful impact, that the partnership with the PAP Foundation is a continuation of our proud commitment to support the patient communities we aim to serve and the organizations that provide patients, families and caregivers the critical support they need, and our strategy and goals. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates (including Molgradex), the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs (including our IMPAPLA and IMPALA-X studies of Molgradex), the ability to obtain the necessary patient enrollment for our product candidates in a timely manner (including our IMPAPLA and IMPALA-X studies of Molgradex), the ability to successfully identify exploratory product pipeline candidates, the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex, AeroVanc and amikacin/fosfomycin that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional equity capital if needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. Contacts: PAP Foundation: Brenna Carey, MS, PhD (brennac@papfoundation.org) PAP Foundation Coordinator (513) 636-8916 Savara: Ioana C. Hone (ir@savarapharma.com) (512) 961-1891 For IR: Solebury Trout Gitanjali Jain Ogawa (Gogawa@troutgroup.com) (646) 378-2949 For Media: Neon InteractivePatrick Wallace (patrick@neoninteractive.com) (619) 200-7856
